Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Center for Drug Evaluation and Research | CDER

Center for Drug Evaluation and Research | CDER
            
                        CDER Offices and Divisions
          Meeting Presentations | Drugs
          CDER Exclusivity Board


                        Accelerating Rare disease Cures (ARC) Program
          CDER Contact Information
          CDER Manual of Policies & Procedures | MAPP
          Frequently Asked Questions about CDER
          Reports & Budgets | CDER Home
          About FDA
          FDA Organization
          Center for Drug Evaluation and Research | CDER
          Office of New DrugsCenter for Drug Evaluation and Research | CDER Office of New Drugs

    
Share
    Post
    Linkedin

    Email
    PrintThe Office of New Drugs (OND) ensures that safe and effective drugs and biologics are available to the American people. OND includes eight review offices with 27 review divisions. OND’s role is twofold: review applications and make an approval decision; set guidance and policy to ensure an efficient review process. OND reviews drug applications, interacts with the pharmaceutical industry and ultimately decides whether the benefits of a drug outweigh the known risks.

What We Do:

Provide regulatory oversight for investigational studies during drug development.
	Make decisions regarding marketing approval for new (innovator or non-generic) drugs, including decisions related to changes to already marketed products.
	Provide guidance to regulated industry on a wide variety of clinical, scientific, and regulatory matters.
	Communicate with the pharmaceutical industry to achieve the common goal of more efficient drug development.
	Oversee the 21st Century Review initiative, which is a set of performance standards CDER follows when conducting drug reviews. The goal of this initiative is to make the drug review process organized and integrated, and ensure all decision makers are heard.
	Update and maintain the Drugs@FDA database, which contains information about FDA-approved brand name and generic prescription and over-the-counter (OTC) human drugs and biological therapeutic products. The database includes most of the drug products approved since 1939.
	Maintain and update information about current drug shortages, and answers frequently asked questions about drug shortages.
	Maintain a searchable database of post-market studies and clinical trials for drugs and biological products.
	Regulate OTC drugs.
	Regulate drug labeling for human prescription drugs to ensure they contain essential scientific information needed for the safe and effective use of the drug.Office Organization

Office of New Drugs – Immediate Office
	Office of Cardiology, Hematology, Endocrinology and Nephrology (OCHEN) – Cardiology and Nephrology, Diabetes, Lipid Disorders, and Obesity, General Endocrinology, Nonmalignant Hematology
	Office of Drug Evaluation Sciences
	Office of Immunology and Inflammation (OII)– Dermatology and Dentistry,  Gastroenterology, Hepatology and Nutrition, Pulmonology, Allergy and Critical Care, Rheumatology and Transplant Medicine
	Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine (ORPRUM) – Pediatric and Maternal Health, Rare Diseases and Medical Genetics, Urology, Obstetrics and Gynecology
	Office of Infectious Diseases (OID) – anti-infective products; antiviral products, transplant and ophthalmology products.
	Office of Neuroscience – neurology products, psychiatric products, anesthesia, analgesia and addiction products
	Office of Nonprescription Drugs (ONPD)- nonprescription products (marketed under Over-the-counter (OTC) monographs and under NDAs).
	Office of Oncologic Diseases (OOD) - oncology products; non-malignant hematology products; issues related to hematology oncology toxicology.
	Office of Specialty Medicine (OSM) - drug products used in the image-based diagnosis and monitoring of diseases as well as ophthalmology productsContact Us

OND Office and Division Contact Information (PDF)

E-mail: ONDCommunications@fda.hhs.gov | Telephone: 301-796-0700 | Fax: 301-796-9856

Office of New Drugs, Immediate Office - Mail Stop 6311, 10903 New Hampshire Avenue, Silver Spring, MD 20993

Related Resources

Provides quick links to databases and other relevant Web pages

Office of New Drugs (OND) Annual Reports
	Drugs@FDA Database
	Provides information about FDA-approved brand name and generic prescription and over-the-counter human drugs and biological therapeutic products. Drugs@FDA includes most of the drug products approved since 1939.
	Drug Application and Approval Process - "Questions and Answers"
	Frequently asked questions and answers about the drug application and approval process. Submit a question and your question, with the answer, may be added to this list.
	Drug Shortages
	Includes information on current drug shortages, how to report drug shortages, resolved drug shortages, drugs to be discontinued, and answers to frequently asked questions about drug shortages.
	Office of Oncologic Diseases (OOD)
	Includes information about OODP, which regulates drug and therapeutic biologic treatments for cancer.
	Pediatric Product Development
	Includes information about FDA initiatives related to improving medical product research in children.
	Postmarket Requirements and Commitments
	Includes a searchable database of information on postmarket studies and clinical trials for drugs and biological products.
	Rare Diseases Program
	Regulation of Nonprescription Products
	Includes information about the Office of Drug Evaluation IV, which regulates over-the counter (OTC) drugs. OTC drug products are those drugs that are available to consumers without a prescription.
	Labeling Policy Team
	Reorganization of the Office of New Drugs with Corresponding Changes to the Office of Translational Sciences and the Office of Pharmaceutical Quality

                                                                                  Content current as of:
      06/24/2022Center for Drug Evaluation and Research | CDER
            
          
                        CDER Offices and Divisions
          Meeting Presentations | Drugs
          CDER Exclusivity Board


                        Accelerating Rare disease Cures (ARC) Program
          CDER Contact Information
          CDER Manual of Policies & Procedures | MAPP
          Frequently Asked Questions about CDER
          Reports & Budgets | CDER
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop